IDIOPATHIC PULMONARY FIBROSIS
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental IPF drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called HZN-825 in people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. The trial aimed to see if the drug could slow the decline in lung function over 52 weeks. About 153 adul…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 09:07 UTC
-
Lung fibrosis drug study halted early
Disease control TerminatedThis study tested new single treatments for idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. It enrolled 46 adults aged 40 and older with stable IPF. The study was terminated early, and results are not yet available.
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:58 UTC
-
New IPF drug trial halted: what happened?
Disease control TerminatedThis study tested a new medicine called GSK3915393 for people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The trial aimed to see if the drug could slow lung function decline, but it was terminated early. About 15…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Lung scarring drug trial halted midway – what we know
Disease control TerminatedThis study tested a drug called vixarelimab to see if it could improve lung function in people with two types of lung scarring: idiopathic pulmonary fibrosis (IPF) and lung scarring linked to scleroderma (SSc-ILD). About 286 adults took either the drug or a placebo for 52 weeks, …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug aims to quiet chronic cough in lung disease patients
Symptom relief TerminatedThis study tested an experimental drug called BI 1839100 to see if it could reduce chronic coughing in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants took different doses of the drug or a placebo for 12 weeks. Coughing was me…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated May 18, 2026 12:07 UTC
-
Sleep apnea treatment studied for IPF patients
Knowledge-focused TerminatedThis study looked at whether using a CPAP machine (a device that helps keep airways open during sleep) could reduce abnormal acid reflux and lung inflammation in people with idiopathic pulmonary fibrosis (IPF) who also have sleep apnea. The study planned to enroll 7 participants …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: NA • Sponsor: University of Arizona • Aim: Knowledge-focused
Last updated May 26, 2026 08:55 UTC